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ABSTRACT 
Centpropazine is anew antidepressant with minimal anticholinergic effects in preclinical animal 
models. In this study centpropazine has been compared with imipramine in a double blind randomised 
multicentric study. A total of 159 patients of major depressive disorder (79 in centpropazine group and 
80 in imipramine group) from four centres were included in this trial. Each patient was randomised to 
receive either centpropazine in a dose of 40 to 120 mg per day or imipramine in a dose of 50 to 150 mg 
per day for a period of six weeks. The antidepressant efficacy of centpropazine was comparable to 
imipramine but anticholinergic side effects were four times less than imipramine. This establishes 
centpropazine as an effective antidepressant with remarkably safer tolerability profile. 
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One of the still unmet needs in the treatment 
of depression is the availability of antidepressants 
with better tolerability profile despite claims made 
by most of them. Centpropazine, 1-(p-propionyl 
phenoxy)-3(N4-phenylpiperaziny!)-propane-2-ol, is 
a new antidepressant belonging to aryloxypropa-
nolamine series of compounds (Rastogi et a!., 
1972). Pharmacologically it has shown 
antidepressant activity in preclinical screening 
tests for evaluating an antidepressant (Prasad et 
al.,1967). These include antagonism of reserpine 
induced ptosis, hypotension, sedation and 
potentiation of amphetamine induced hyperactivity 
in mice. Centpropazine does not antagonize the 
pilocarpine induced salivation and its antitremorine 
activity is weaker than imipramine. 
Neurochemically it decreased the density of 5HT, 
and 5HT2 receptors in the cortical regions following 
prolonged administration in rats whereas fi 
receptor down regulation was not observed 
(Hussain et al.,1988). In another study it was found 
that centpropazine has an affinity with alpha 1-
adrenoceptor but the affinity is two times lower 
than that of imipramine (Dikshit et al.,1993). 
Centpropazine inhibited inositol phosphate but 
cyclic AMP accumulation in rat brain was not 
altered. In normal male volunteers centpropazine 
was well tolerated in single and multiple doses 
(Gupta et al.,1989). The efficacy studies in patients 
of depression revealed its therapeutic activity in 
80% patients (Srivastava et al.,1992). We report 
here in this communication results of multicentric 
double blind randomized Phase III clinical trial. 
MATERIAL & METHOD 
The study was a double blind parallel 
trial comparing centpropazine with imipramine 
at following centres in India. 
Deptt.of Psychiatry KG.Medical College, 
Lucknow 
Deptt. of Psychiatry National Institute of 
Mental Health & 
Neurosciences, 
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Bangalore. 
Deptt. of Psychiatry Seth G.S. Medical 
College, Bombay. 
Deptt. of Psychiatry Govt. Medical College, 
Patiala. 
Patients of either sex diagnosed to be 
suffering from Major Depressive Disorder in 
accordance with DSM-III R (Diagnostic and 
Statistical Manual of Mental Disorders Ed.Ill 
Revised) were included at each centre. The 
protocol was approved by Institutional Ethics 
Committees following permission from The Drugs 
Controller General of India. An informed consent 
was obtained from each patient or a near relative 
if the patient was unable to execute such a consent. 
Patients below 18 years or above 55 years and/or 
patients'with a history of depression lasting for more 
than 2 years or with severe depression requiring 
electroconvulsive therapy or other forms of therapy 
and patients with renal, hepatic, cardiac or 
respiratory diseases were excluded from the trial. 
Selected patients underwent a 7 day placebo period 
after evaluation on 24 item Hamilton Depression 
Rating Scale (HDRS) and Rating Scale for Side 
Effects (Asberg). Any patient showing a decrease 
of 25% or more on HDRS was excluded from the 
study at the end of placebo period. Patients were 
now assigned to either receive centpropazine or 
imipramine on the basis of randomization chart 
supplied to the centre from Central Drug Research 
Institute, Lucknow. Subsequently each patient was 
evaluated on HDRS and ASES scales at weekly 
intervals upto six weeks. Every patient was also 
assessed on Clinical Global Impression Scale 
(CGIS). The patients received either centpropazine 
(40 to 120 mg/day) or imipramine(50 to 150 mg/ 
day) in two divided doses for a duration of six 
weeks. The maximum dose was achieved within 
a period of one week. During this period of 6 weeks 
each patient was required to stay in the hospital. 
Complete haemogram,serum biochemical 
investigations and electrocardiogram were done 
before (0 week) and after (+6 weeks) the trial. 
The predrug and postdrug mean HDRS 
scores at weekly intervals were statistically 
analysed using t-test. 
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RESULTS 
A total of 159 patients (40 patients from 
each centre) suffering from major depressive 
disorder were included in the study. Out of 40 
patients twenty patients each received 
centpropazine and imipramine at individual 
centre according to randomization chart. The 
data from each centre was analysed separately 
and then pooled for the purposes of presentation. 
Centpropazine Group 
Seventy nine patients received six week 
treatment with centpropazine. Out of these 40 were 
males and 39 were females. The age of these 
patients ranged between 20 to 55 years (mean 
35.2 ± 9. 8). Fiftyfive patients (38 males, 17 
females) completed the six week study and 
remaining 24 patients dropped out due to factors 
unrelated to the drug (unwilligness to stay in the 
hospital/ physical illness) The mean HDRS scores 
were significantly reduced from second week 
onward and this lowering, was maintained till the 
end of the study at each centre. The mean HDRS 
score decreased from 25.3±2.4 (initial) to 
8.2±6.3(final) after the centpropazine therapy. The 
initial and final (i.e. at the end of 6weeks of therapy) 
mean HDRS scores of depressed patients at each 
centre have been depicted in Figure 1. The 
percentage lowering of more than 75 % was 
observed in 27 patients, between 50 to 74 % in 17 
patients, between 25 to 49% in 9 patients and less 
than 25% in 2 patients (Tablel). The side effect 
analysis showed that side effects were present in 
only 10 patients which included presence of 
dryness (5), giddiness (3), headache (2), tremor(l) 
and constipation(l). They have been depicted in 
Figure 3. On Clinical Global Impression Scale 
(CGIS) it was found that 28 patients were very 
much improved, 18 patients improved moderately, 
8 patients experienced mild improvement and one 
patient did not show any response (Table 2). 
Imipramine Group 
Out of 80 patients who were treated with 
imipramine, 41 were males and 39 were females. 
The age of these patiants ranged between 18 to 
55 years (mean 36.14 ± 9.37). Fiftyfive patients 
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TABLE 1 
SHOWING PERCENTAGE REDUCTION IN HDRS SCORE 
WITH CENTPROPAZINE AND IMIPRAMINE THERAPY 
3 dropped out from the study within first two 
weeks as mentioned above. 
Group >75% 
Centpropazine 27 
(n=55) 
Imipramine 30 
(n=54) 
50-74% 
17 
14 
25-49% 
9 
9 
<24% 
2 
1  HDRS Score 
TABLE 2 
ASSESSMENT ON CLINICAL GLOBAL 
IMPRESSION SCALE AFTER CENTPROPAZINE 
AND IMIPRAMINE THERAPY 
Group 
Centpropazine 
(n=55) 
Imipramine 
(n=54) 
Very 
Much 
Improved 
28 
29 
Moderate 
Improve-
ment 
18 
18 
Mild 
Improve-
ment 
8 
6 
No 
Improve-
ment 
1 
1 
completed the study. Remaining 26 patients 
dropped out during iiie course of study. Major 
reason of dropout was their unwillingness to stay 
in the hospital except in three patients where it 
was due to development of severe 
anticholinergic side effects. The mean HDRS 
scores decreased from 25.2 ± 3.9 (initial) to 7,4 
± 5.3 (final) after six week therapy with 
imipramine. The initial and final (i.e. at the end 
of 6weeks of therapy) mean HDRS scores of 
depressed patients at each centre have been 
depicted in Figure 2. The mean HDRS scores 
were significantly decreased second week 
onwards. The percentage lowering in individual 
HDRS scores was more than 75% in 30 patients 
and between 50 to 74% in 14 patients following 
imipramine therapy (Table 1). The anticholinergic 
side effects (Figure 3) were present in 40 patients 
and these include dryness of mouth (33), 
constipation (16), palpitation (10), tremor (9), 
dizziness (6), perspiration (4), physical 
tiredness (4), orthostatic symptoms(4), 
drowsiness (4), sexual symptoms (2) and 
headaches). On clinical Global Impression Scale 
(CGIS) 29 patients were very much improved, 
18 patients improved moderately whereas 6 
patients showed mild improvement and one 
patient did not improve (Table 2). Four patients 
developed orthostatic symptoms and out of these 
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Fig.1: Initial and final mean HDRS 
scores following Centpropazine Therapy 
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Fig.2- initial and final .nean HDRS 
scores following Imipramine Therapy 
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Fig. 3. Comparative incidence of side 
effects with Centpropazine A fmipramine 
during the study 
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DISCUSSION 
This multicentric, double blind, 
randomised and parallel study suggests that the 
efficacy of centpropazine is comparable with that 
of a standard drug imipramine. The advantage 
of centpropazine over imipramine is clearly 
evident due to its better tolerability profile. This 
will allow clinicians to use a higher dose without 
the risk of unpleasurable anticholinergic side 
effects and will provide an edge over 
conventional tricyclic antidepressants in elderly 
de pressed patients and in patients with suicidal 
intent owing to its wider therapeutic margin. The 
dropout rate was marginally less with 
centpropazine (30%) than with imipramine (33%) 
as three patients in imipramine group dropped 
early in the study and were due to anticholinergic 
side effects. As far as incidence of anticholinergic 
side effects is concerned they are present in 40/ 
80 (50%) cases with imipramine as compared 
to only 10/79 (12.7%) cases in centpropazine 
group. However in none of patients these were 
severe enough to stop or reduce the dosage. 
The antidepressant drugs have been 
mainly classified into tricyclics and specific serotonin 
reuptake inhibitors. The third group of monoamine 
oxidase inhibitors may have serious interactions 
with certain foodstuffs containing tyramine. The 
tricyclic antidepressants have been shown to 
produce anticholinergic, cardiac and serious 
overdosage effects especially in elderly depressed 
patients (Blackwell,1981). A search for safer and 
more effective antidepressants continues. This has 
resulted in newer tricyclic drug like amoxapine, 
dothiepin and maprotiline, tetracyclic compounds 
like mianserin and mirtazapine and specific 
serotonin reuptake inhibitors like fluoxetine, 
sertraline, paroxetine and citalopram. The 
development of centpropazine is also a step in the 
same direction. It has shown a wider safety margin 
as compared to imipramine in acute toxicity studies 
and could be safer than tricyclics in accidental 
overdosage by suicidal patients which is a persistent 
risk in patients with suicidal intent. 
It has been claimed that newer 
antidepressant drugs lack anticholinergic effects, 
FAVA et al. 
produce less cardiotoxicity and are safer in 
overdose. Amoxapine arid maprotiline are toxic 
as well as epileptogenic in overdosage (Kulig et 
al.,1982; Knudsen & Heath,1984). However, 
amoxapine induces no cardiotoxicity but 
maprfitiline is equally if not greater than currently 
used TCAs. Mirtazapine, a tetracyclic compound 
caused somnolence, weight gain and amblyopia 
in some cases (Smith et al.,1990). Mianserin 
another tetracyclic drug has been associated with 
agranulocytosis and aplastic anemia. Zimelidine, 
though introduced enthusiastically, had to be 
withdrawn from market following reports of 
Guillain - Barre Syndrome (Martindale,1989). 
Viloxazine caused nausea, vomiting, weight loss 
and may precipitate migraine (Blackwell,1981). 
Trazodone aggravated the ventricular arrhythmias 
in patients with preexisting cardiac disease 
(Janowsky et ai.,1983). This drug also produced 
severe priapism in several cases (Scher et 
al.,1983). Nomifensin has been associated with 
massive intravascular haemolysis (Lylloff et 
al.,1982). Fluoxetine, a prototype of serotonin 
reuptake inhibitors, has been associated with 
gastrointestinal side effects such as anorexia and 
insomnia (Nelson, 1997). In comparison to above 
mentioned newer antidepressants, centpropazine 
has shown a remarkably safer profile in depressed 
patients. The Drugs Controller General of India 
has granted marketing permission and it has been 
licensed for marketing to a pharmaceutical 
company recently. 
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